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Abstract—Dietary lipids are reported to affect the blood pressure in both humans and experimental animal models with
hypertension. In the present study, 2-kidney, 1-clip (2K1C) hypertensive rats were treated with the modified fatty acid
tetradecylthioacetic acid (TTA) from the time of clipping or after hypertension was established. TTA treatment
attenuated the development of hypertension and reduced established 2K1C hypertension. The mRNA level of renin in
the clipped kidney and the plasma renin activity were markedly reduced, and the plasma angiotensin II level tended to
decrease after TTA treatment. In addition, TTA reduced the mRNA level of angiotensinogen in white adipose tissue.
Prevention of organ damage was demonstrated by normal urinary excretion of protein, maintained serum albumin, lower
heart weight, and clearly reduced vascular, glomerular, and tubulointerstitial damage in the nonclipped kidney. Renal
function was not affected as estimated by unchanged plasma creatinine. Furthermore, the serum levels of triacylglycerol
and cholesterol were reduced by TTA. The serum fatty acid composition was changed, resulting in a favorable increase
of oleic acid. However, the levels of all of the omega-3 fatty acids and of linoleic acid were reduced, and no change
was seen in the level of arachidonic acid, but the urinary excretion of 8-iso-prostaglandin F2 was declined. In
conclusion, TTA attenuated the development of hypertension, reduced established hypertension, and prevented the
development of organ damage in 2K1C rats, possibly by reducing the amounts of the vasoconstrictors angiotensin II and
8-iso-prostaglandin F2 and by inducing a favorable increase of oleic acid in serum. (Hypertension. 2006;48:460-466.)
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Elevated blood pressure is closely related to increase incardiovascular death from events like stroke, myocardial
infarction, and chronic renal failure1 and is defined as one of
the risk factors for the metabolic syndrome.2,3 Other risk
factors include insulin resistance, hyperglycemia, and ele-
vated serum triacylglycerol, which are conditions that are
improved in rats after treatment with the modified fatty acid
tetradecylthioacetic acid (TTA).4
The pleiotropic effects of TTA seem to be mediated through
both peroxisome proliferator-activated receptor (PPAR)–depen-
dent and PPAR-independent mechanism4 and include changes in
the fatty acid composition of both liver and serum in rats.5–7
Based on these potential possibilities to change composition of
the metabolic system, and because the fatty acid composition of
cholesteryl ester and phospholipids in serum has been related to
the blood pressure level in humans,8–10 we examined the effect
of TTA on hypertension in the present study.
An inducible model of high blood pressure is the 2-kidney,
1-clip (2K1C) hypertension model, where the increased blood
pressure is induced after clipping of one renal artery. This is
an angiotensin II–dependent model of hypertension with
increased level of plasma renin and angiotensin, and hyper-
tension is usually established 3 to 4 weeks after clipping.11
Long-term 2K1C hypertension is followed by organ damage
as enlarged heart and damage of the nonclipped kidney with
increased urinary protein excretion and declining glomerular
filtration rate.11
The intention of the present study was to examine the
effect of TTA on blood pressure in 2K1C hypertensive rats, a
model without the other risk factors of the metabolic syn-
drome. Our working hypothesis was that TTA would interfere
with the renin–angiotensin system in this high-renin model of
hypertension and reduce the blood pressure through lowering
of the plasma renin activity. Because TTA is reported to
change the fatty acid composition, we investigated the rela-
tion between the fatty acid composition and 8-iso-prostaglan-
din (PG)F2 to blood pressure in 2K1C hypertensive rats.
Methods
An expanded Methods section can be found in an online supplement
(available at http://hyper.ahajournals.org).
Animals
The protocol was approved by the Norwegian State Board for
Biological Experiments With Living Animals. Male Wistar rats
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(Møllegaard Breeding Laboratory, Ejby, Denmark), weighing 180 to
200 g at the start of the experiment, were used for establishing
2K1C hypertension.
Two experiments were performed. In the first experiment, TTA
treatment was started either at the day of clipping or 5 weeks after
clipping when the hypertension was established and compared with
untreated 2K1C rats. The rats were killed 12 weeks after clipping. In
the second experiment, TTA treatment was started at the day of
clipping and compared with untreated 2K1C rats, and the rats were
killed 6 months after clipping. The systolic blood pressure was
measured by means of the tail-cuff method (UGO BASILE) in
unanesthetized rats.
Real-Time Quantitative RT-PCR
Total RNA was purified from frozen tissue, and the mRNA levels of
renin, angiotensinogen, PPAR, PPAR, and PPAR were deter-
mined by relative quantification using the standard curve method and
normalized to 18S rRNA.
Analysis of Vasoactive Substances and Lipids
The renin activity and the concentration of angiotensin II were
measured in plasma, whereas triacylglycerol, cholesterol, albumin,
and creatinine levels were measured in serum. Urine was collected
for 24 hours, and the urinary excretion of 8-iso-PGF2 and proteins
were measured. The fatty acids composition in serum and liver were
analyzed.
Enzyme Activities in Liver
The activities of carnitine palmitoyltransferase–II12 and fatty acyl-
coenzyme A (CoA) oxidase13 were measured in hepatic postnuclear
fraction.
Light Microscopy
One-hundred randomly sampled glomeruli were analyzed regarding
segmental or global sclerosis and podocytes with adsorption droplets
and/or pseudocysts. Twenty microscopic fields were investigated for
tubulointerstitial damage. Glomerular sclerosis and tubulointerstitial
damage were assessed using a semiquantitative scoring system (0 to
4): grade 0 indicates no lesions, grade 1 indicates lesions in 25%,
grade 2 indicates lesions in 25% to 50%, grade 3 indicates lesions in
50% to 75%, and grade 4 indicates lesions in (almost) the entire
capillary tuft area/tubulointerstitial area. Atrophy in the clipped
kidney was semiquantitatively graded (0 to 3): grade 0 indicates no
atrophy, grade 1 indicates slight atrophy, grade 2 indicates moderate-
to-marked atrophy, and grade 3 indicates global atrophy.
Statistical Analysis
Data are presented as meanSEM. The data were evaluated by a
2-sample variance Student’s t test (2-tailed distribution).
Results
In the untreated 2K1C rats, hypertension was established 3 to
4 weeks after clipping and was stable throughout the rest of
the observation period of 12 weeks (Figure 1). TTA treatment
Figure 1. Changes in the systolic blood pressure in untreated
and TTA-treated 2K1C rats. *Signiﬁcantly different from
untreated rats, P0.001.
Figure 2. A, Gene expression of renin in clipped and nonclipped
kidneys from untreated and TTA-treated 2K1C rats. The results
are presented relative to 18S rRNA and normalized to clipped
controls, arbitrary units. *Signiﬁcantly different from clipped kid-
ney in untreated rats, P0.05. B, Plasma renin activity at the
time of clipping and 12 weeks after clipping in untreated and
TTA-treated 2K1C rats. *Signiﬁcantly different from untreated
rats at the time of clipping, P0.05. C, Plasma angiotensin II
level 12 weeks after clipping in untreated and TTA treated 2K1C
rats. ND indicates not determined.
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from the time of clipping attenuated the development of
hypertension in 2K1C rats (Figure 1). Twelve weeks after
clipping, the systolic blood pressure in the untreated group
was 1813 mm Hg, whereas the systolic blood pressure in
the TTA-treated group was 1503 mm Hg (P0.001; Figure
1). When TTA treatment was started 5 weeks after clipping,
the systolic blood pressure was reduced from 1689 mm Hg
to 1555 mm Hg (P0.05) within 2 weeks, which is similar
to that of rats treated with TTA from the time of clipping
(Figure 1).
TTA treatment reduced the renin mRNA level in the
clipped kidney by50% (P0.05), but TTA had no effect on
the renin mRNA level in the nonclipped kidney, where this
level is normally very low (Figure 2A). The renin mRNA
level was significantly higher in the clipped kidney compared
with the nonclipped kidney independent of treatment regime
(P0.01; Figure 2A). The plasma renin activity at the time of
clipping was equal in untreated and TTA-treated rats (Figure
2B). Twelve weeks after clipping, the plasma renin activity
was markedly increased in the untreated rats but was not
changed in the TTA-treated rats (Figure 2B). The plasma
level of angiotensin II tended to decrease in TTA-treated rats
(Figure 2C), but this was not significant (P0.06). The
mRNA level of angiotensinogen, which is a precursor of
angiotensin II, was reduced in epididymal white adipose
tissue after TTA treatment (Figure 3A), but this level was
increased in liver by TTA (Figure 3B).
Circulating fatty acids are reported to interfere with blood
pressure,8–10 and it was, therefore, of interest to see how the
fatty acid composition of serum was affected by TTA. TTA
treatment increased the levels of palmitoleic acid, oleic acid,
and icosatrienoic acid, but the levels of palmitic acid and
stearic acid were unchanged in serum (Table 1). In addition,
the level of linoleic acid and all of the omega-3 polyunsatu-
rated fatty acids (PUFAs) were reduced after TTA treatment
(Table 1).
The isoprostane 8-iso-PGF2 is formed nonenzymatically
from the attack of a superoxide radical on esterified arachidonic
acid. Although the level of arachidonic acid in serum was not
affected (Table 1), the urinary excretion of 8-iso-PGF2 was
significantly decreased after TTA treatment (Figure 4).
The effect of TTA on the fatty acid composition in liver
was similar to that seen in serum (data not shown). TTA and
its 9 desaturated metabolite TTA:1n-8 were recovered in
both serum (Table 1) and liver (data not shown) of TTA-
treated rats.
TTA treatment significantly reduced the serum levels of
triacylglycerol and cholesterol (Table 2). Concomitant with
this, the activities of carnitine palmitoyltransferase-II and
fatty acyl-CoA oxidase were increased (Table 2), suggesting
that TTA increased the capacity for fatty acid oxidation.
However, TTA did not significantly change the mRNA levels
of PPAR, PPAR, or PPAR in clipped or nonclipped
kidneys (data not shown).
Figure 3. Gene expression of angiotensinogen in epididymal
white adipose tissue (A) and liver (B) from untreated and TTA-
treated 2K1C rats 12 weeks after clipping. The results are pre-
sented relative to 18S rRNA and normalized to untreated rats,
arbitrary units. *Signiﬁcantly different from untreated rats,
P0.05.
Figure 4. Excretion of 8-iso-PGF2 in urine from untreated and
TTA-treated 2K1C rats measured 12 weeks after clipping. *Sig-
niﬁcantly different from untreated rats, P0.05.
TABLE 1. Selected Fatty Acids (g/100 g Fatty Acids) in
Serum From Untreated and TTA-Treated 2K1C Rats 3 Months
After Clipping
Fatty Acid Untreated TTA-Treated
Palmitic acid (16:0) 22.980.60 22.340.48
Stearic acid (18:0) 7.710.25 7.110.21
Palmitoleic acid (16:1n-9) 0.460.02 0.660.03*
Oleic acid (18:1n-9) 13.320.24 24.221.21*
Icosatrienoic acid (20:3n-9) 0.220.06 2.160.05*
Linoleic acid (18:2n-6) 21.591.15 12.851.15*
-Linolenic acid (18:3n-6) 0.390.06 0.610.08*
Dihomo--linolenic acid (20:3n-6) 0.490.05 1.120.03*
Arachidonic acid (20:4n-6) 20.470.54 18.580.89
-Linolenic acid (18:3n-3) 0.660.05 0.280.05*
Eicosapentaenoic acid (20:5n-3) 0.370.03 0.190.02*
Docosapentaenoic acid (22:5n-3) 0.590.06 0.120.01*
Docosahexaenoic acid (22:6n-3) 2.060.08 0.680.06*
TTA ND 1.790.16
TTA:1n-8 ND 2.060.24
ND indicates not detected.
*Significantly different from untreated rats, P0.05.
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To evaluate the role of TTA in the prevention of organ
damage induced by hypertension, 2K1C rats were treated
with TTA for 6 months from the time of clipping. At the end
of this long-term study, the systolic blood pressure was
2136 mm Hg in the untreated rats and 1688 mm Hg in the
TTA-treated rats (P0.001). The urinary protein excretion
was increased 5-fold (17540 versus 294 mg/24 h1;
P0.01) during the experiment (Figure 5A), accompanied by
decreased serum albumin level (341.2 versus 462 gL1;
P0.01; Figure 5B). However, serum creatinine was un-
changed at the end of the experiment (Figure 5C). The urinary
protein excretion (Figure 5A), serum albumin level (Figure
5B), and serum creatinine (Figure 5C) were not affected
during the experiment in the TTA-treated rats. The body
weight and the heart weight were significantly lower in the
TTA-treated rats, whereas TTA treatment did not affect the
kidney weights (Table 3).
TTA-treated rats clearly developed less morphological
damage in the nonclipped kidney 6 months after clipping
compared with untreated rats (Figure 6). There were only
minor arterial and arteriolar changes in the nonclipped kidney
in TTA-treated rats in contrast to marked vascular wall
changes with media hypertrophy, intima proliferation, hyali-
nosis, and fibrinoid necrosis in untreated rats. Hypertension-
associated glomerular changes in the nonclipped kidney
(adsorption droplets, pseudocysts, segmental, and global
sclerosis; Figure 7) as well as tubulointerstitial damage were
significantly reduced in TTA-treated rats (Table 4). There
was no significant difference in the atrophy score of the
clipped kidney in untreated and TTA-treated rats (Table 4).
Discussion
Elevated blood pressure is closely related to increase in
cardiovascular death from events like stroke, myocardial
infarction, and chronic renal failure.1 In the present study, we
wanted to examine the effect of TTA on secondary hyperten-
sion induced by clipping of one renal artery to see whether
TTA could interfere with the renin–angiotensin system, the
lipid metabolism, and development of hypertension.
In the present article, we show for the first time that TTA
attenuated the development of hypertension in 2K1C when
TTA was given from the day of clipping, and, in addition,
TTA reduced the blood pressure when hypertension was
established. In agreement with previous findings, 12 weeks
after clipping, the clipped kidney contained a higher level of
renin mRNA than the nonclipped kidney, as shown previously.14
In addition, TTA treatment had no effect on the renin mRNA
level in the nonclipped kidney, but markedly reduced this level
in the clipped kidney. This was accompanied by reduced plasma
renin activity and a strong tendency to decrease the plasma
angiotensin II level by TTA. Thus, regulation of the renin–an-
giotensin system seems to be important for the effect of TTA on
Figure 5. Urinary excretion of protein (A), serum albumin (B),
and serum creatinine (C) in untreated and TTA-treated 2K1C
rats at the time of clipping and 6 months after clipping. *Signiﬁ-
cantly different from untreated rats at the time of killing, P0.01.
TABLE 2. Serum Lipids and the Hepatic Mitochondrial and
Peroxisomal -Oxidation Capacities in Untreated and
TTA-Treated 2K1C Rats 3 Months After Clipping
Lipids and Enzymes Untreated TTA-Treated
Serum lipids, mmol/L
Triacylglycerol 2.040.27 0.700.12*
Cholesterol 3.110.51 1.350.12*
Enzyme activities, nmol/mg protein per min
Carnitine palmitoyl-transferase II 3.840.33 16.821.23*
Fatty acyl-CoA oxidase 12.20.9 144.14.9*
*Significantly different from untreated rats, P0.05.
TABLE 3. The Weight of the Body, Heart, and Kidneys in
Untreated and TTA-Treated 2K1C Rats 6 Months After Clipping
Body and Organ
Weight Untreated TTA-treated
Body weight, g 52514 47512*
Heart weight, g 1.80.09 1.60.06*
Kidney weight, g
Nonclipped 2.50.12 2.40.19
Clipped 1.20.17 1.00.10
*Significantly different from untreated rats, P0.05.
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blood pressure by reducing the production of angiotensin II,
which is the main vasoconstrictor in 2K1C hypertension. Acti-
vation of PPAR has been reported to decrease the expression of
the angiotensin-II type I receptor,15,16 but although TTA is a
pan-PPAR ligand,4 no change was seen in the mRNA level of
PPAR in clipped or nonclipped kidneys after TTA treatment.
Hypertension is one of the complications in obesity, and
the adipose angiotensinogen gene expression has been shown
to play a role in both adipose tissue development and
hypertension of obese patients,17–19 representing a link be-
tween obesity and hypertension. The increased activities of
carnitine palmitoyltransferase–II and fatty acyl-CoA oxidase
in liver of TTA-treated 2K1C rats suggested that both the
mitochondrial and the peroxisomal -oxidation were in-
creased, and this was accompanied by reduced serum triac-
ylglycerol, as demonstrated previously in normotensive
rats.20 The increased -oxidation of fatty acids by TTA could
lead to lowered amounts of the adipose tissue, as we have
found previously,21 a finding that may contribute to reduced
production of angiotensinogen.22 Interestingly, TTA seemed
to have a tissue-specific effect on the gene expression of
angiotensinogen, because the mRNA level of angiotensino-
gen was reduced in white adipose tissue and increased in
liver. This is in line with findings by others showing that
high-fat feeding differently affects the mRNA level of angio-
tensinogen in adipose tissue and liver of mice.23 Because fat
surrounds many of the muscular arteries, changes in adipose
angiotensinogen mRNA level and, thus, the production of
angiotensin II might affect the systemic vascular resistance.24
Olive oil contains a high amount of oleic acid and is
reported to decrease blood pressure in humans.25–27 Here we
show that the attenuation of hypertension after TTA treatment
is accompanied by increased levels of oleic acid and its
metabolites palmitoleic acid and icosatrienoic acid, probably
because of increased 9 desaturase activity.28 An elevated
level of palmitic acid9 and a reduced level of stearic acid8 in
serum cholesteryl esters are associated with higher risk of
Figure 6. Histological changes in the nonclipped kidney in
untreated (A, C, and E) and TTA-treated (B, D, and F) 2K1C rats,
6 months after clipping (trichrome acid fuchsin orange-G). A and
B, Overview showing pronounced tubulointerstitial damage with
tubular dilation, cast formation and interstitial ﬁbrosis in A (scale
bar, 1 mm). C and D, Marked arterial wall changes with media
hypertrophy and intimaproliferation in C. Normal artery of the
same size in D (scale bar, 50 m). E and F, Arteriole with ﬁbrin-
oid necrosis (3), glomerulus with segmental sclerosis (Œ) in E,
normal arterioles (3) and glomeruli with minor changes in F
(scale bar, 100 m).
Figure 7. Hypertension-associated glomerular changes in non-
clipped kidney from untreated 2K1C rats, 6 months after clip-
ping. A, Adsorption droplets in podocytes (3). B, Podocyte with
adsorption droplets and a pseudocyst (*). C, A minor (3) and
(D) a major focus of segmental sclerosis (periodic acid Schiff
reaction, scale bar, 20 m in A and B and 50 m in C and D).
TABLE 4. Quantitative and Semiquantitative Evaluation of
Morphologic Changes in Nonclipped and Clipped Kidney in
Untreated and TTA-Treated 2K1C Rats 6 Months After Clipping
Morphologic Changes Untreated TTA-Treated
Nonclipped kidney
Adsorption droplets, % glomeruli 16.663.81 5.541.87*
Pseudocysts, % glomeruli 9.172.50 2.201.01*
Segmental sclerosis, mean score 0.940.31 0.040.01*
Tubulointerstitial damage, mean score 1.700.47 0.220.09*
Clipped kidney
Atrophy, score 1.600.31 1.330.41
*Significantly different from untreated rats, P0.05.
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hypertension; however, in the present study, no change was
seen in the serum levels of these fatty acids.
Dietary supplementation with omega-3 PUFAs, such as
eicosapentaenoic acid and docosahexaenoic acid, lowers
blood pressure and prevents the development of hyperten-
sion,29–32 possibly because of the ability of omega-3 PUFAs
to replace and, thus, reduce the cellular membrane levels of
arachidonic acid.33 Despite the attenuation of 2K1C hyper-
tension by TTA treatment, the level of all of the omega-3
acids in serum was reduced, probably as a result of the
increased mitochondrial and peroxisomal -oxidation.12
Reduced serum linoleic acid is observed in patients and
experimental animal models with hypertension,9,10 whereas a
high level of dihomo--linolenic acid and arachidonic acid in
serum cholesteryl esters has been shown to be associated with
increased risk of hypertension.8,9 In the present experiment,
TTA decreased the level of linoleic acid and increased the
level of dihomo--linolenic acid, whereas no change was
seen in the level of arachidonic acid. Linoleic acid is the
essential precursor of the longer omega-6 PUFAs, and ara-
chidonic acid can be synthesized from linoleic acid via
-linolenic acid and dihomo--linolenic acid in liver. The
biosynthesis of arachidonic acid is catalyzed by 5 and 6
desaturases, and we have found previously that TTA in-
creases the level of arachidonic acid in normotensive rats34
and upregulates the gene expression of these desaturases in
rat liver (O.G. Gudbrandsen, T.H. Røst, R.K. Berge, unpub-
lished data, 2006). Because the rate-determining desaturases
and intermediates are increased, it may be reasonable to
assume that the generation of arachidonic acid was increased.
However, because no change was seen in arachidonic acid in
serum or liver, the conversion of arachidonic acid to other
compounds, such as prostaglandins, may be increased by
TTA in the present experiment.
The isoprostane 8-iso-PGF2 is produced by free-radical
peroxidation of esterified arachidonic acid and is an ex-
tremely potent renal vasoconstrictor.35,36 In the present study,
the attenuation of hypertension in 2K1C by TTA was associated
with reduced excretion of 8-iso-PGF2 in urine, whereas the
level of arachidonic acid in serum and liver was unchanged. The
lack of correlation between 8-iso-PGF2 and arachidonic acid
may be explained by changes in the peroxisomal -oxidation
capacity, because 8-iso-PGF2 can be oxidized by peroxi-
somes.37 Because the peroxisomal -oxidation activity was
enhanced by TTA, TTA may protect 2K1C rats from the
vasoconstrictive effect of 8-iso-PGF2 by increasing the perox-
isomal -oxidation.
A blood pressure–lowering drug should also reduce or
inhibit development of organ damage. Six months after
clipping, TTA treatment not only attenuated hypertension but
also abolished proteinuria, in contrast to untreated 2K1C rats,
which developed heavy proteinuria and a decline in serum
albumin. TTA also protected the heart, because the heart
weight was lower than in untreated rats. Most important, the
morphological changes were markedly attenuated during
TTA treatment in the nonclipped kidney, whereas the clipped
kidney was protected by the clip and showed similar changes
in untreated and TTA-treated rats.
Perspectives
We have shown previously that TTA improve several risk
factors of the metabolic syndrome, such as insulin resistance,
hyperglycemia, and hyperlipidemia, in rats. In the present
study, we show for the first time that TTA also prevented the
development of hypertension and organ damage in rats. This
effect seems to be mediated through the renin–angiotensin
system, which plays a major role in human types of hyper-
tension. The combination of lipid-lowering effect and blood
pressure reduction makes TTA a promising drug, because
high lipid levels and high blood pressure are major challenges
in clinical practice. A further perspective will be to examine
the effect of TTA in genetic hypertension where the renin–
angiotensin system is less upregulated than in renal hyper-
tension. Because the blood pressure–lowering effect of TTA
seems to be mediated at least partly via the renin–angiotensin
system, further studies on the effect of TTA in rat models
with normal renin levels, such as the spontaneously hyper-
tensive rats, will be performed.
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